Active substance
Benzylpenicillin
- SFDA 2
- US FDA 41
- Health Canada 3
- WHO EML 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| PENICILLIN G INJ 1 MILLION IU | 1,000,000 IU | Powder for solution for injection/infusion · Intramuscular use | 1 Vial | SAR 2.10 | NCE · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| PENICILLIN-G SOD 500000 IU VIAL | 500000 IU | Powder for solution for injection/infusion · Intramuscular use | 1 Vial | SAR 1.75 | NCE · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PFIZERPEN | 5,000,000 UNITS/VIAL; 20,000,000 UNITS/VIAL | injectable · injection | PFIZER | Prescription | 30 Aug 1968 |
| PENICILLIN G POTASSIUM IN PLASTIC CONTAINER | 20,000 UNITS/ML; 40,000 UNITS/ML; 60,000 UNITS/ML | injectable · injection | BAXTER HLTHCARE | Prescription | 25 Jun 1990 |
| PENICILLIN G SODIUM | 5,000,000 UNITS/VIAL | injectable · intramuscular, intravenous | SANDOZ | Prescription | 26 Feb 2001 |
| PENICILLIN G POTASSIUM | 5,000,000 UNITS/VIAL; 20,000,000 UNITS/VIAL | injectable · injection | SANDOZ | Prescription | 30 Aug 2002 |
| PENICILLIN G POTASSIUM | 1,000,000 UNITS/VIAL; 5,000,000 UNITS/VIAL; 20,000,000 UNITS/VIAL | injectable · injection | HQ SPECLT PHARMA | Prescription | 23 Jul 2009 |
| PENICILLIN G POTASSIUM | 5,000,000 UNITS/VIAL; 20,000,000 UNITS/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 18 Aug 2009 |
| PENICILLIN G POTASSIUM | 5,000,000 UNITS/VIAL; 20,000,000 UNITS/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 26 Oct 2018 |
| PENICILLIN G POTASSIUM | 20,000,000 UNITS/VIAL | injectable · injection | PFIZER | Discontinued | 6 Feb 1947 |
| PFIZERPEN G | 50,000 UNITS; 100,000 UNITS; 200,000 UNITS; 250,000 UNITS; 400,000 UNITS; 800,000 UNITS | tablet · oral | PFIZER | Discontinued | 2 Mar 1948 |
| PFIZERPEN G | 400,000 UNITS/5ML | for solution · oral | PFIZER | Discontinued | 13 Sep 1951 |
| PENICILLIN | 200,000 UNITS/5ML; 400,000 UNITS/5ML | for solution · oral | TEVA | Discontinued | 27 May 1964 |
| PENICILLIN-2 | 250,000 UNITS/5ML | for solution · oral | TEVA | Discontinued | 27 May 1964 |
| PFIZERPEN | 1,000,000 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | PFIZER | Discontinued | 30 Aug 1968 |
| PENICILLIN G POTASSIUM | 200,000 UNITS; 250,000 UNITS; 400,000 UNITS; 500,000 UNITS | tablet · oral | TEVA | Discontinued | 26 Jun 1979 |
| PENICILLIN G POTASSIUM | 200,000 UNITS; 250,000 UNITS; 400,000 UNITS; 800,000 UNITS; 500,000 UNITS | tablet · oral | MYLAN | Discontinued | 10 Mar 1980 |
| PENICILLIN G POTASSIUM | 1,000,000 UNITS/VIAL; 5,000,000 UNITS/VIAL; 10,000,000 UNITS/VIAL; 20,000,000 UNITS/VIAL | injectable · injection | WATSON LABS INC | Discontinued | 13 Sep 1988 |
| PENICILLIN G SODIUM | 5,000,000 UNITS/VIAL | injectable · intramuscular, intravenous | WATSON LABS INC | Discontinued | 13 Sep 1988 |
| PENICILLIN G POTASSIUM | 1,000,000 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | SANDOZ | Discontinued | 30 Aug 2002 |
| PENICILLIN G POTASSIUM | 400,000 UNITS | tablet · oral | IVAX SUB TEVA PHARMS | Discontinued | |
| PENICILLIN G POTASSIUM | 1,000,000 UNITS/VIAL; 20,000,000 UNITS/VIAL; 5,000,000 UNITS/VIAL; 10,000,000 UNITS/VIAL | injectable · injection | APOTHECON | Discontinued | |
| PENICILLIN G POTASSIUM | 5,000,000 UNITS/VIAL; 1,000,000 UNITS/VIAL; 500,000 UNITS/VIAL; 200,000 UNITS/VIAL; 20,000,000 UNITS/VIAL | injectable · injection | LILLY | Discontinued | |
| PENICILLIN G POTASSIUM | 250,000 UNITS | tablet · oral | APOTHECON | Discontinued | |
| PENTIDS '400' | 400,000 UNITS | tablet · oral | APOTHECON | Discontinued | |
| PENTIDS '800' | 800,000 UNITS | tablet · oral | APOTHECON | Discontinued | |
| PENICILLIN G POTASSIUM | 250,000 UNITS | tablet · oral | LILLY | Discontinued |
16 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| PENICILLIN G SODIUM FOR INJECTION, USP | 02220261 | 1000000 UNIT / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | FRESENIUS KABI CANADA LTD |
| PENICILLIN G SODIUM FOR INJECTION, USP | 02220288 | 5000000 UNIT / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| PENICILLIN G SODIUM FOR INJECTION, USP | 02220296 | 10000000 UNIT / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | FRESENIUS KABI CANADA LTD |
WHO WHO Model List of Essential Medicines (2025)
- 6.2.1. Access group antibiotics · core
First choice: Bacterial pneumonia (Community-acquired pneumonia - severe) [children]; First choice: Acute malnutrition in infants, children or adolescents (complicated) [children]; First choice: Congenital syphilis [children]; First choice: Syphilis; First choice: Sepsis without septic shock (co-prescribed with gentamicin); Second choice: Bacterial meningitis
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt) (EMLc); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt) (EMLc) | Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt) - 5.1.6.1. Medicines for bacterial central nervous system infections · core
Second choice: Bacterial meningitis
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Combinations containing Benzylpenicillin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.